BillionToOne
What They Do
BillionToOne provides noninvasive prenatal genetic testing, with its molecular counting technology, increasing the resolution of disease detection using cell-free DNA by over 1000x.
Its flagship product, UNITY Screen, is the only non-invasive prenatal test (NIPT) that can test both a pregnant mother and her baby for single-gene disorders such as sickle cell disease, cystic fibrosis, and spinal muscular atrophy.
Why We Invested
BillionToOne empowers expecting families with the highest-fidelity non-invasive fetal testing that has ever been commercially available. From a single blood-draw, the company is able to assess maternal carrier status in a range of diseases and then reflex to single gene fetal DNA testing with an extraordinary sensitivity. This test enables the detection of fetal diseases that previously would only have been detectable with invasive procedures like amniocentesis.
Furthermore, UNITY Screen addresses the large % of pregnancies in America in which a paternal carrier screen is not possible due to an absent father.
The company’s team is exceptional, both technically and commercially, and is driving rapid clinical adoption of BTO’s market-leading test while developing similarly best-in-class approaches to other molecular diagnostics.